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ONO-2952 is a novel and selective inhibitor of translocator protein 18 kDa
that reduces stress-induced defecation and visceral hyperalgesia in rat
models.
Aim
To evaluate the efficacy and safety of ONO-2952 in females with irritable
bowel syndrome with diarrhoea in an exploratory proof-of-concept study.
Methods
A randomised, double-blind, placebo-controlled study was conducted at 49
US centres. Two hundred subjects with irritable bowel syndrome with diar-
rhoea (Rome III criteria) were randomised to ONO-2952 20 mg, or 60 mg,
or placebo. Subjects recorded irritable bowel syndrome symptoms daily
during a 2-week baseline period, the 4-week treatment period and for
4 weeks post-treatment. The co-primary endpoints were change from base-
line to week 4 in abdominal pain, stool consistency and stool frequency.
Results
Improvements in irritable bowel syndrome symptoms were seen with
ONO-2952 over placebo in per-protocol analyses for all three co-primary
endpoints, but these did not reach statistical significance at the 5% level.
The largest improvement was seen with ONO-2952 60 mg. ONO-2952 was
well tolerated with a safety profile similar to that of placebo. Most adverse
events were mild or moderate in severity and not treatment related.
Conclusion
ONO-2952 showed evidence of clinical efficacy in reducing irritable bowel
syndrome-related symptoms in female subjects with irritable bowel syn-
drome with diarrhoea, and further evaluation is, therefore, warranted to
assess its potential as a treatment for irritable bowel syndrome with diar-
rhoea (NCT01844180).
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INTRODUCTION
Irritable bowel syndrome (IBS) is a common chronic
functional gastrointestinal disorder that affects approxi-
mately 11% of the population worldwide.1 It is charac-
terised by abdominal pain or discomfort associated with
altered bowel habits.2–4 Three main IBS subtypes are
recognised, determined by stool consistency pattern: IBS
with diarrhoea (IBS-D), IBS with constipation (IBS-C)
and IBS with mixed constipation and diarrhoea (IBS-
M).2 IBS significantly impacts on health-related quality
of life (QoL)5 and is a substantial socioeconomic burden
due to the high healthcare costs, lost work days and
reduced productivity6, 7 associated with the condition.
The pathophysiology of IBS remains unclear; however,
the most important mechanisms include visceral sensitiv-
ity, abnormal gut motility and autonomic nervous sys-
tem dysfunction.8 Genetics, the gut microbiome, immune
activation, altered intestinal permeability and brain–gut
interactions are also thought to play a role.9
The management of IBS is challenging due to the
complex nature of the disease. Management options
include dietary and lifestyle modifications and psycho-
logical and pharmacological therapies.10 There are cur-
rently only three approved pharmacological treatments
for IBS-D, which have been shown to improve both
abdominal pain and diarrhoea.11 The 5-HT3 antagonist
alosetron was initially approved in 2000, but due to seri-
ous gastrointestinal adverse effects, its use is now limited
to women with severe IBS-D symptoms that are refrac-
tory to other treatments. Eluxadoline (a mixed l-opioid
receptor agonist and d-opioid receptor antagonist) and
rifaximin (a broad-spectrum, non-absorbable, gut-specific
antibiotic) were both approved in 2015.11, 12 Although
these new treatments have expanded the treatment
options available for IBS-D, there remains a need for
further effective and well-tolerated therapies.11
Translocator protein 18 kDa (TSPO) is a five-domain
transmembrane protein that is highly expressed in ster-
oid-producing tissues, including the glial cells within the
brain.13–16 TSPO ligands can modulate the synthesis of
neurosteroids that act as allosteric modulators of excita-
tory and/or inhibitory neurotransmitter receptors.17–20
ONO-2952 is a novel and selective antagonist that binds
with high affinity to TSPO in rat brain and human
tumour cell-line membrane preparations. The antago-
nism of TSPO by ONO-2952 has been shown to reduce
stress-induced defecation and visceral hyperalgesia in rat
models.21, 22 It is hypothesised that IBS symptoms and
symptoms of stress feed into one another, so that a
reduction in stress leads to a reduction in IBS symptoms.
ONO-2952 has been granted Fast Track status for IBS-D
by the United States Food and Drug Administration
(FDA). Phase 1 studies in healthy adults have shown
ONO-2952 to be safe and well tolerated.23, 24
This Phase 2, exploratory study evaluated the efficacy,
safety and tolerability of orally administered ONO-2952
(20 and 60 mg once daily for 4 weeks) vs. placebo in
female subjects with IBS-D. The aim of this study was to
identify signals of efficacy over a relatively short treat-
ment period prior to larger scale clinical evaluation. The
primary objective of the study was to investigate the effi-
cacy of ONO-2952 in abdominal pain and stool symp-
toms. Secondary objectives included assessment of effects
on stool urgency, abdominal discomfort, adequate relief
of IBS symptoms or IBS-related pain, QoL and evalua-
tion of safety and tolerability.
MATERIALS AND METHODS
Study design
This double-blind, randomised, placebo-controlled study
enrolled subjects from April 2013 to July 2014 at 49 US
study centres. The trial was designed, conducted and
reported in compliance with US federal and local regula-
tions and the ethical principles of the Declaration of Hel-
sinki and International Conference on Harmonization
Good Clinical Practice guidelines. An institutional review
board-approved informed consent form was signed by
all subjects before their participation in the trial
(ClinicalTrials.gov identifier: NCT01844180).
The study consisted of a screening period of up to
30 days, a 4-week, on-treatment period, then a 4-week,
treatment-free follow-up period (Figure 1a). Subjects com-
pleted an electronic diary (e-diary) to record IBS-related
symptoms, adequate symptom relief, dates of onset and ter-
mination of menstrual bleeding, and rescue medication use.
At visit 3, eligible subjects were randomly assigned (1:1:1)
to treatment with oral placebo, ONO-2952 20 mg or ONO-
2952 60 mg once daily for 4 weeks. Subjects were assigned
to treatment groups by site personnel using an Interactive
Web Response System and central randomisation scheme
(Cenduit Interactive Response Technology).
Study population
Eligible subjects were adult females aged 18–65 years
who met the Rome III criteria for IBS-D and had a diag-
nosis of IBS-D (defined as loose/watery stools in ≥25%
and hard/lumpy stools in <25% of defecations)
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Figure 1 | (a) Study design and (b) subject disposition. *Based on actual treatment received. **Pharmacokinetic
concentrations on day 29 that were below the limit of quantification and so were consistent with noncompliance with
the study protocol. FAS, full analysis set; IBS, irritable bowel syndrome; PPS, per-protocol set; q.d., once daily; SAF,
safety analysis set.
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confirmed by the pre-treatment (days 14 to 1) IBS-D
symptom diary and physician evaluation. Other inclusion
criteria were an average daily score of ≥3.0 (on a 0- to
10-point numerical rating scale) for IBS-related worst
abdominal pain during the 2-week baseline window
(days 14 to 1); ≥1 stool with a consistency of type 6
or 7 on ≥2 days/week and ≤1 stool with a consistency of
type 1 or 2 on <2 days/week using the Bristol Stool Scale
(BSS)25 during the 2-week baseline window; and com-
pleted self-assessment of IBS symptoms using a subject
e-diary on ≥5 days/week during the 2-week baseline.
Subjects were also required to have undergone a flexible
sigmoidoscopy or colonoscopy within the past 5 years or
after the onset and/or significant worsening of IBS symp-
toms, with a normal result based on clinical findings.
Pregnant women were excluded and eligible patients had
to meet one of the following criteria: (i) surgically ster-
ilised or post-menopausal, (ii) females of child-bearing
potential who are nonlactating agreed to use a double
barrier method of contraception for the study, and (iii)
negative b-hCG test for pregnancy at both visit 1 and
visit 3. There was no requirement for subjects to have a
specific Hamilton Anxiety Rating Scale (HAM-A),
Hamilton Depression Rating Scale (HAM-D) or Per-
ceived Stress Scale (PSS) value on entry into the study.
Key exclusion criteria were as follows: structural abnor-
malities of the gastrointestinal tract other than oesophagi-
tis or gastritis; clinically significant biochemical
abnormality within the past 6 months; diagnosis with a
major psychiatric disorder that required hospitalisation
within the past 2 years; faecal occult blood test indicating
an inflammatory gastrointestinal disorder; upper gastroin-
testinal symptoms that would impact on IBS symptoms or
their assessments; history of abdominal surgery or Crohn’s
disease, ulcerative colitis, diabetes mellitus, lactose malab-
sorption, malabsorption syndromes or coeliac sprue; or
any other medical conditions that might interfere with
assessment of safety or efficacy of the study drug.
Medications likely to interfere with the assessment of
ONO-2952 had to be discontinued at least 14 days prior
to randomisation.a Laxatives, enemas, colonics and
hydrotherapy were prohibited from 7 days prior to ran-
domisation. The use of cytochrome P450 (CYP) inhibi-
tors, inducers and substrates was prohibited during
randomisation and the on-treatment period of the study.
Subjects agreed to remain on a stable diet and maintain
their usual level of physical activity.
Analysis sets defined prior to study unblinding
included the following: the safety analysis set (SAF; all
subjects who received ≥1 dose of study medication); the
full analysis set [FAS; all subjects in the SAF who had
≥1 post-baseline efficacy assessment – i.e. ≥5 valid diary
entries within a week period (2-week period during the
baseline period)]; and the per-protocol set (PPS). Strict
criteria were applied to the PPS to obtain a population
of ONO-2952-treated subjects to provide the best possi-
ble chance of observing a signal of efficacy in this
exploratory study. The PPS comprised all subjects in the
FAS except for those with violations of inclusion/exclu-
sion criteria that might affect the evaluation of the co-
primary efficacy endpoints (IBS-D symptoms), subjects
who used concomitant medications that could have
impacted efficacy assessments, and subjects who were
inadequately treated with study medication. Subjects who
were insufficiently exposed to ONO-2952 (compliance
<80%, n = 2) or those with excess exposure (compliance
>120%, n = 1) were excluded from analysis.
Rescue medication
Subjects who had severe IBS symptoms for >3 consecu-
tive days during the period from 14 days prior to ran-
domisation could take loperamide (up to 4 mg/day).
Subjects who had severe IBS-related abdominal pain
could take acetylsalicylic acid (up to 650 mg/day) or
paracetamol (up to 1000 mg/day). Daily doses of acetyl-
salicylic acid or paracetamol were also permitted for IBS-
unrelated symptoms (e.g. fever or headache), and
restricted to a maximum of twice during the 14 days
prior to randomisation until the end of the on-treatment
period, and four times during the 4-week follow-up
period.
Study outcomes
Given this was the first assessment of efficacy in IBS
patients, co-primary endpoints as recommended in FDA
Guidance26 were selected to assess the effect of treatment
on two major IBS signs and symptoms: abnormal defeca-
tion (both frequency and consistency) and abdominal
pain. The co-primary endpoints consisted of the follow-
ing three variables measured on continuous scales: (i)
daily ratings of worst abdominal pain experienced during
aMedications likely to interfere with the assessment of ONO-2952: anx-
iolytics, anticonvulsants, alpha and beta blockers, calcium-channel
blockers, opioids, analgesics (except acetylsalicylic acid and paraceta-
mol), 5-HT3 antagonists, 5-HT4 agonists, macrolides, antacids that
contain Al or Mg, prostaglandins, sulfasalazine, infliximab, H2 blockers
and proton-pump inhibitors judged to impact on IBS symptoms or on
symptom assessment, colchicine, leuprolide modafinil or armodafinil,
iron supplements, otilonium bromide, pinaverium bromide, pepper-
mint oil and antiobesity agents.
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the past 24 h (measured on a 0–10 numeric rating scale),
(ii) daily ratings of stool consistency on the 7-point BSS
and (iii) frequency of stools per week measured via the
daily e-diary. For each outcome, the primary analyses
were based on the mean change from baseline to week 4.
In this exploratory study, the primary outcomes were
continuous variables rather than binary measures of
treatment responsiveness because continuous measures
are more sensitive to between-group comparisons. How-
ever, secondary analyses included binary measures of
response to treatment.
A daily responder in abdominal pain intensity was
defined as a subject who experienced a decrease of ≥30%
compared with the baseline average in the score recorded
for worst abdominal pain in the past 24 h. A weekly
responder in abdominal pain intensity was defined as a
subject who experienced a decrease of ≥30% compared
with baseline in the weekly average of worst abdominal
pain in the past 24 h.
A daily stool consistency responder was defined as a
subject who experienced BSS classifications of <5 for all
bowel movements of the day or who had no bowel
movement for that day. A weekly stool consistency
responder was defined as a subject who experienced a
≥50% reduction in the number of days per week with at
least one stool that has a BSS classification of type 6 or 7
compared with baseline.
Secondary efficacy endpoints (analysed or sum-
marised using the PPS unless otherwise indicated) were
based on the FDA definitions of specific weekly and
daily responders for pain and stool parameters.26 Sec-
ondary endpoints included the overall proportion of
weekly and daily responders for abdominal pain inten-
sity, stool consistency and the composite of abdominal
pain and stool consistency. The daily composite end-
point required that the worst abdominal pain rating be
≥30% below the baseline average daily worst abdominal
pain and no bowel movement with a BSS classification
of ≥5 for the same day. Other secondary endpoints
were the proportion of subjects reporting adequate
symptom relief over time and overall weekly adequate
relief rate; change from baseline over time in the ‘num-
ber of pain-free days’ and ‘days without any urgency’
per week; and total scores and changes from baseline
over time in the IBS-QoL scale and IBS Symptom
Severity Scale (IBS-SSS; compared using the FAS),26–29
Exploratory endpoints (compared using the FAS)
included changes from baseline over the treatment per-
iod for the planned psychiatric endpoints of the HAM-
A, HAM-D and the PSS.
Safety monitoring consisted of physical examinations,
vital signs, 12-lead electrocardiography, clinical labora-
tory tests and surveillance for adverse events (AEs).
Blood samples were collected pre-dose and at ~3 h
post-dose on day 29 to measure the concentration of
ONO-2952 in plasma.
Statistical analyses
Determination of sample size. As this was a Phase 2
exploratory study, the sample size was determined by the
ability to detect a signal of efficacy in IBS-D subjects
with ONO-2952. It was planned to analyse 150 subjects
(50 per treatment arm). A 25% dropout rate was esti-
mated, and thus, approximately 195 female subjects with
IBS-D were to be randomised.
Co-primary endpoints. ONO-2952 20 and 60 mg doses
were compared with placebo using a general linear
model, with additional factors added as appropriate,
using the PPS. A separate model was applied for each
endpoint, giving three models in all. In each model, the
dependent variable was the endpoint in question. The
model included the baseline value (of the corresponding
primary efficacy measure) and treatment as explanatory
variables. In addition, the following explanatory factors
and covariates known to affect IBS symptoms were
included: race dichotomised into white/nonwhite, body
mass index (BMI; as continuous covariate); and men-
strual bleeding. All comparisons used a two-sided test at
the alpha = 0.05 level of significance, uncorrected for
multiple comparisons, with P values presented with point
estimates and 95% confidence intervals (CIs). Adjusted
least squares means for the treatment effects and 95%
CIs were also presented.
Sensitivity analyses
In addition to using the FDA-recommended threshold
for defining daily and weekly responders for abdominal
pain intensity (≥30% reduction from baseline),26 pre-
planned sensitivity analyses were undertaken for both
the abdominal pain intensity endpoint and abdominal
pain and stool consistency composite endpoints at week
4 using thresholds of ≥40% and ≥50% reduction in
abdominal pain intensity from baseline.
Exploratory analyses
To permit exploration of the time course of the co-pri-
mary endpoints from baseline through week 4 and to
assess the impact of excluding subjects in the FAS from
the PPS while accommodating missing data, mixed-
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model repeated-measures models were applied to each of
the three co-primary efficacy measures, initially using the
PPS and then the FAS. To identify covariates that may
have influenced outcomes, additional analyses were
undertaken using the PPS, considering factors/covariates
such as age, ethnicity, BMI, menstrual bleeding, mean
stool consistency, baseline PSS score, mean weekly score
of the worst abdominal pain experienced during the past
24 h at baseline, number of days per week with ≥1 stool
having a BSS classification of type 6 or 7 at baseline and
number of stools per week at baseline.
RESULTS
Participants
Two hundred female subjects were randomised; 189
(94.5%) completed the study and 11 discontinued treat-
ment prematurely (Figure 1b). Reasons for discontinua-
tion were noncompliance with the study protocol
(n = 4), withdrawal of consent (n = 3), loss to follow-up
(n = 1) and other reasons (n = 3). No subject
discontinued due to an AE. All subjects were included in
the SAF and FAS and 132 (66.0%) of these met the
stringent criteria for the PPS (Figure 1b).
Demographics and baseline characteristics were com-
parable between the three treatment arms (Table 1),
except for a higher percentage of subjects with baseline
BMI ≥30 kg/m2 in the ONO-2952 60 mg group (49.3%
vs. 36.4% and 42.9% in the ONO-2952 20 mg and pla-
cebo groups, respectively). All had baseline PSS scores
indicative of low stress (i.e. scores <14) and psychiatric
scores (HAM-A and HAM-D) indicative of a normal
population. Subjects in all treatment arms averaged ~25
bowel movements per week and had a mean BSS stool
consistency of approximately 6. Treatment compliance
(assessed by counting tablets, not with a dosing calendar)
was 99.6%, 99.5% and 98.7% in the ONO-2952 60 mg,
ONO-2952 20 mg and placebo groups, respectively.
Efficacy
Co-primary endpoints. Over the 4-week on-treatment
period, a greater decrease in IBS symptoms was evident





q.d. (n = 41)
ONO-2952 60 mg
q.d. (n = 45)
Age, years, mean (s.d.) 47.8 (12.5) 46.8 (12.5) 46.4 (12.1)
BMI, kg/m2, mean (s.d.) 29.73 (6.55) 29.24 (7.01) 32.12 (7.25)
Ethnicity, n (%)
American Indian/Alaskan native 1 (2.2) 0 (0) 1 (2.2)
Asian 0 (0) 0 (0) 1 (2.2)
Black or African American 5 (10.9) 4 (9.8) 5 (11.1)
Native Hawaiian or other Pacific Islander 1 (2.2) 0 (0) 0 (0)
White 38 (82.6) 37 (90.2) 38 (84.4)
Mixed 1 (2.2) 0 (0) 0 (0)
Menstrual bleeding – yes, n (%)
At any time 19 (41.3) 15 (36.6) 20 (44.4)
During the baseline period 12 (26.1) 6 (14.6) 16 (35.6)
During week 4 8 (17.4) 3 (7.3) 11 (24.4)
Abdominal pain during baseline, mean (s.d.) 6.36 (1.50) 6.24 (1.36) 6.01 (1.71)
No. of bowel movements/week during
baseline, mean (s.d.)
25.71 (11.96) 23.25 (14.27) 27.20 (14.76)
No. of days per week with ≥1 stool classed as BSS type
6/7 during baseline, mean (s.d.)
6.08 (1.36) 5.76 (1.40) 5.89 (1.50)
Stool consistency (BSS classification) during baseline,
mean (s.d.)
6.11 (0.57) 5.92 (0.56) 5.89 (0.54)
PSS score during baseline, mean (s.d.) 9.20 (5.35) 9.66 (5.25) 9.31 (6.21)
HAM-A score during baseline, LS, mean (s.d.)* 5.2 (4.55) 5.4 (4.6) 5.7 (5.34)
HAM-D score during baseline, LS, mean (s.d.)* 2.6 (3.79) 2.8 (3.61) 2.7 (4.29)
BMI, body mass index; BSS, Bristol Stool Score; PSS, Perceived Stress Scale; QD, once daily; s.d., standard deviation.
* Full analysis set for HAM-A and HAM-D.
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in both ONO-2952 groups, compared with placebo, for
all three co-primary endpoints (Table 2). The largest
decreases in abdominal pain and stool frequency were
observed in subjects receiving ONO-2952 60 mg. How-
ever, subject numbers were not high enough to consis-
tently achieve statistical significance with between-group
comparisons at the 5% level. For stool consistency, mean
decreases in the number of days per week with ≥1 stool
of BSS type 6 or 7 were similar in both ONO-2952
groups. Neither were significantly different vs. placebo at
week 4 (Table 2).
Mean weekly IBS symptoms were similar in each
treatment group at baseline. At each time point on-
treatment and during follow-up, the largest improve-
ments from baseline in IBS symptoms, relative to pla-
cebo, were seen in the ONO-2952 60 mg group
(Figure 2). These improvements became evident at
1–2 weeks after dosing, reaching statistical significance
at week 3 for abdominal pain (P < 0.05) but missing
statistical significance at week 4. Stool consistency also
showed improvement over 4 weeks compared with pla-
cebo, but was not statistically significant at the 5%
level. No differences were observed in weekly stool fre-
quency scores between groups. Following the end of
treatment, there was a rapid return to baseline for
abdominal pain and stool consistency scores in the
ONO-2952 60 mg group.
Secondary endpoints. FDA responder analyses: Com-
pared with placebo, a greater proportion of subjects trea-
ted with ONO-2952 60 mg met FDA responder criteria
over the 4-week treatment period in overall daily response
for a composite endpoint of both pain intensity (using a
≥30% reduction in pain threshold) and stool consistency
(20.0% vs. 6.5%) and single endpoints of abdominal pain
(53.3% vs. 37.0%) or stool consistency (26.7% vs. 10.9%;
Figure 3 and Table S1), although the differences did not
reach statistical significance at the 5% level. A similar pat-
tern was observed for overall weekly response (Figure 3b).
Pre-planned sensitivity analyses were performed on the
overall daily responders over the 4-week treatment period
for abdominal pain response as well as for the composite
endpoint of both pain intensity and stool consistency
using ≥40% and ≥50% change from baseline thresholds for
abdominal pain response. Using both thresholds, there
were higher proportions of responders for the composite
endpoint in the ONO-2952 60 mg group (20.0% and
13.3%, respectively), compared with the ONO-2952 20 mg
(12.2% and 9.8%, respectively) and placebo groups (6.5%
and 6.5%, respectively; Table S1). For abdominal pain, a
statistically significant difference in the odds ratio (OR)
for percentage of responders was observed following
ONO-2952 60 mg treatment, compared with placebo, for
change from baseline of ≥50% (OR: 2.89; 95% CI: 1.04–
8.00; P = 0.04; Table S1).
Other responder analyses and quality-of-life and psychi-
atric assessments: During the treatment period, a higher
proportion of responders in the ONO-2952 60 mg group
reported adequate relief from symptoms (68.9%), com-
pared with the ONO-2952 20 mg (56.1%) and placebo
(56.5%) groups, which was most evident at weeks 2, 3
Table 2 | Change from baseline to week 4 in mean weekly scores for worst abdominal pain experienced during the
past 24 h, number of days per week with ≥1 stool of BSS type 6 or 7, and weekly number of stools (on-treatment
period, per-protocol set)
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P value for zero
difference
– 0.7162 0.1519 – 0.2396 0.2406 – 0.6498 0.5733












CI, confidence interval; LS, least squares; q.d., once daily.
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and 4. This difference between treatments across the
4-week treatment period was not statistically significant.
The proportion of responders then decreased in each
treatment group during the follow-up period. The biggest
decrease in the proportion of subjects who reported ade-
quate relief was seen in the 60 mg group (from 68.9%
during treatment to 31.1% during follow-up), while in
the placebo group 45.7% reported adequate relief in the
follow-up phase. This difference between groups was not
statistically significant (Figure S1). The number of days
without pain or urgency vs. baseline was also higher in
the ONO-2952 60 mg group, compared with the ONO-
2952 20 mg and placebo groups, during the treatment
and follow-up periods (Figure S2).
Mean baseline values were similar for all treatment
groups for IBS-QoL and IBS-SSS total scores, HAM-A,
HAM-D and PSS total scores (Table S2). At the end of
the on-treatment period (day 29), improvements from
baseline were evident in each treatment group for IBS-
QoL and IBS-SSS and for the three psychiatric assess-
ments.
Rescue medication use (paracetamol, acetylsalicylic
acid or loperamide) as permitted by the protocol was
low (<12%) in all treatment groups during the treatment
period (Table S3).
Safety
The incidence of treatment-emergent AEs (TEAEs) was
similar for subjects in the ONO-2952 60 mg and placebo
groups (47.9% and 47.6%, respectively) and slightly
lower for those in the ONO-2952 20 mg group (39.4%)
(Table 3). Most TEAEs were mild or moderate in sever-
ity and considered unrelated to study treatment. No sub-
jects discontinued treatment due to TEAEs. The most
frequently reported TEAEs (by system organ class) were
gastrointestinal disorders (placebo: 23.8%, ONO-2952
20 mg: 12.1%, ONO-2952 60 mg: 16.9%), infections and
infestations (placebo: 15.9%, ONO-2952 20 mg: 10.6%,
ONO-2952 60 mg: 14.1%), and nervous system disorders
(placebo: 6.3%, ONO-2952 20 mg: 10.6%, ONO-2952
60 mg: 4.2%) (Table 3). None of the differences between
treatment groups were considered clinically relevant.
There were no clinically significant CNS-related AEs.
Eleven subjects in each treatment group experienced
TEAEs that were considered related to study treatment.
The most frequent of these were abdominal pain (pla-
cebo: n = 2, ONO-2952 60 mg: n = 1) and nausea (pla-
cebo: n = 1, ONO-2952 20 mg: n = 1, ONO-2952
60 mg group: n = 3). One subject receiving ONO-2952
60 mg experienced moderate constipation considered
probably related to study treatment, which resolved
spontaneously. This subject was also taking oral bupro-
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Figure 2 | Least-squares mean (95% CI) change from
baseline in weekly scores for (a) worst abdominal pain
experienced in the past 24 h, (b) number of days per
week with ≥1 stool of BSS type 6 or 7, and (C) weekly
number of stools (per-protocol set). *P < .05;
#P < 0.10 vs. placebo; $P < 0.10 vs. placebo over weeks
1–4 (repeated measures analysis). BSS, Bristol Stool
Score; CI, confidence interval.
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associated with constipation.30 No other subject reported
constipation.
Seven subjects experienced severe TEAEs [placebo:
n = 1 (1.6%), ONO-2952 20 mg: n = 4 (6.1%), ONO-
2952 60 mg: n = 2 (2.8%)], all of which were gastroin-
testinal disorders [placebo: abdominal pain (n = 1);
ONO-2952 20 mg: exacerbation of IBS (n = 2), vomiting
(n = 1); ONO-2952 60 mg: exacerbation of IBS (n = 2)],
except for one subject receiving ONO-2952 20 mg
(urinary tract infection). One subject each in the placebo
and ONO-2952 60 mg group experienced serious AEs
(pneumonia and dehydration, and acute cholecystitis,
respectively); none were considered related to study drug.
No deaths were reported.
DISCUSSION
This exploratory study of a TSPO antagonist, ONO-2952,
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(c) Differing thresholds for abdominal pain responder
Figure 3 | Responder analysis for (a) daily responders, (b) weekly responders and (c) daily responders according to
differing thresholds for abdominal pain (on-treatment period, per-protocol set).
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signals of IBS symptom improvement. Although the co-
primary endpoints were not met in this study, effects on
some endpoints did show the potential of ONO-2952 as a
treatment for IBS patients. In this study, subjects treated
with ONO-2952 60 mg generally showed improvements
in IBS symptoms (abdominal pain, stool consistency and
stool frequency) over 4 weeks compared with placebo-
treated subjects. A statistically significant difference in
abdominal pain compared with placebo was observed at
week 3 (P < 0.05). Differences were also seen for stool
consistency compared with placebo over weeks 1–4. These
improvements disappeared during the treatment-free fol-
low-up period, most rapidly for the 60 mg dose, with val-
ues becoming similar again to those of the placebo group.
This rapid return to baseline after stopping of treatment is
another indication that ONO-2952 60 mg may be an
effective treatment for IBS-D (Figure 2).
In addition, a greater percentage of subjects treated
with ONO-2952 60 mg vs. placebo met FDA responder
criteria over the 4-week treatment period and met
responder criteria for abdominal pain at thresholds of
≥40% and ≥50% decrease from baseline. A statistically
significant improvement in abdominal pain with ONO-
2952 60 mg vs. placebo was observed for the ≥50%
threshold (P < 0.05). Improvements were also evident in
a number of secondary endpoints including adequate
symptom relief, number of pain-free days, and number
of days without urgency following treatment with ONO-
2952 60 mg, compared with placebo providing additional
signals for efficacy. There was no apparent difference in
the changes from baseline for IBS-QoL and IBS-SSS;
however, given the scale of the study, these measures
were highly variable, with low likelihood of detecting any
differences.
A dose–response relationship for ONO-2952 was also
evident for both primary and secondary efficacy mea-
sures, with greater improvements in IBS symptoms gen-
erally seen following administration of the 60 mg dose
compared with the 20 mg dose. This observation is con-
sistent with results from a Phase 1, single-dose, positron
emission tomography study in healthy male and female
subjects that demonstrated a higher whole-brain TSPO
occupancy for ONO-2952 60 mg (77.4%) compared with
the 20 mg dose (61.3%).24 The higher whole brain TSPO
occupancy for ONO-2952 60 mg provides a plausible
explanation for the observed dose–response effect; how-
ever, further studies are required to determine whether
doses of ONO-2952 above 60 mg are effective.
Thus, albeit in a relatively small-scale clinical study, the
potential impact on abnormal defecation and abdominal
Table 3 | Summary of most frequently reported (by >1 subject in any treatment group) treatment-emergent adverse
events by MedDRA Preferred Term version 16.1 (safety analysis set)
n (%) Placebo q.d. (n = 63)
ONO-2952
20 mg q.d. (n = 66) 60 mg q.d. (n = 71)
Number of subjects with TEAEs 30 (47.6) 26 (39.4) 34 (47.9)
Abdominal pain 3 (4.8) 0 (0) 1 (1.4)
Abdominal tenderness 2 (3.2) 0 (0) 0 (0)
Diarrhoea 0 (0) 2 (3.0) 0 (0)
Flatulence 2 (3.2) 0 (0) 1 (1.4)
Irritable bowel syndrome 1 (1.6) 2 (3.0) 2 (2.8)
Nausea 2 (3.2) 1 (1.5) 3 (4.2)
Vomiting 0 (0) 2 (3.0) 1 (1.4)
Influenza 2 (3.2) 1 (1.5) 0 (0)
Nasopharyngitis 4 (6.3) 1 (1.5) 4 (5.6)
Upper respiratory tract infection 1 (1.6) 1 (1.5) 2 (2.8)
Urinary tract infection 1 (1.6) 2 (3.0) 0 (0)
Myalgia 0 (0) 0 (0) 2 (2.8)
Headache 3 (4.8) 3 (4.5) 3 (4.2)
Pollakiuria* 2 (3.2) 0 (0) 0 (0)
Cold sweat 0 (0) 2 (3.0) 0 (0)
MedDRA, Medical Dictionary for Regulatory Activities; q.d., once daily; TEAE, treatment-emergent adverse event.
* Frequent daytime urination. Adverse events were collected from time of dosing and were all considered to be TEAEs. The table
is based on actual treatment received. Three subjects were randomised to placebo but had plasma concentrations of ONO-2952
greater than the limit of quantification, so were assigned to the ONO-2952 60 mg treatment group. Two subjects were issued
with incorrect kits in error, so were assigned to their first dispensed treatment (ONO-2952 60 mg).
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pain demonstrated by ONO-2952 is considered highly rele-
vant given that these are the cardinal symptoms of IBS
patients. Indeed, abdominal pain and abnormal defecation
management in IBS currently lacks one unique effective
pharmacological remedy. Although the mechanism by
which stool consistency is altered by ONO-2952 is not fully
understood, preclinical models showed a similar effect;
ONO-2952 prevented restraint stress-induced defecation in
rats at doses corresponding to >50% TSPO occupancy in the
brain.22 In addition, questions are raised as to whether the
effects of ONO-2952 are limited to the central nervous sys-
tem or may also be peripherally mediated. Due to the wide-
spread expression of TSPO throughout the body (TSPO is
found in many regions of the body including the heart, liver,
adrenal and testis, as well as hemopoietic and lymphatic cells
and human iris/ciliary body), it is possible that the effects of
ONO-2952 may not be limited to the CNS.
ONO-2952 was generally well tolerated by female IBS-
D subjects in this study. The majority of AEs were mild
in intensity and were considered to be unrelated to the
study drug. Gastrointestinal disorders were the most
commonly reported AEs, and there were no clinically
relevant AEs involving the CNS. Interestingly, there was
no apparent signal to suggest that constipation was
observed in subjects treated with ONO-2952. Constipa-
tion is the most common AE associated with both elux-
adoline and alosetron in subjects with IBS-D and was
one of the reasons the use of alosetron is now limited to
women with severe refractory IBS-D.7, 31–35
There were limitations to this study. The antagonism of
TSPO by ONO-2952 has been shown to reduce stress-
induced defecation in rat models, which provided a ratio-
nale for testing the compound in IBS-D patients where
stress has been suggested to play an influential role in
symptom generation. However, the subjects who partici-
pated in this study did not appear to be anxious or
stressed. The assessment of several psychiatric parameters
including the PSS, HAM-A and HAM-D was included in
the study, but baseline values across the treatment groups
were all in line with those of a healthy adult population.
No attempt was made to enrol IBS-D patients with a speci-
fic ‘stress’ phenotype as this would have impacted recruit-
ment substantially. All patients had baseline PSS scores
indicative of low stress (i.e. scores <14). HAM-A total
scores in a population of patients with generalised anxiety
disorder were reported as between 20 and 30, while base-
line HAM-A scores in this study for all treatment groups
were from 5.2 to 5.7.36 For the HAM-D scale, a score of 0–
7 is generally accepted to be within the normal range and
scores of 20 or higher indicate moderate, severe or very
severe depression and are usually required for entry into a
clinical trial in depression. Baseline HAM-D scores in this
study for all treatment groups were between 2.6 and 2.8.
There was, therefore, limited scope for improvement in
any of these scales and post hoc analysis could not confirm
any clear correlation between individual improvements in
IBS symptoms such as abdominal pain and changes in
psychiatric parameters.
In addition, although the recommended treatment
duration for studies in IBS-D to formally assess efficacy is
at least 8 weeks,26 the treatment duration in this trial was
limited to 4 weeks, the longest period permitted by avail-
able pre-clinical toxicology data at the time of study con-
duct. However, the 4-week treatment period was
considered appropriate to identify any signals of efficacy
with ONO-2952 and its novel mechanism of action. As
this was an exploratory proof-of-concept study, it was not
formally powered and the analysis of study endpoints was
conducted using an analysis population (PPS) defined to
provide the best possible chance of observing a signal of
efficacy. Given the stage of development of ONO-2952,
this was deemed appropriate. Lastly, the study population
was limited to women as the overall prevalence of IBS in
women is 67% higher than in men.37 Further studies
would be required to determine whether ONO-2952
demonstrates efficacy in men. It is thus acknowledged that
additional clinical trials of larger scale, longer treatment
duration and expanded population will be required to fur-
ther explore the efficacy of ONO-2952 in IBS-D.
In conclusion, treatment with ONO-2952 60 mg
once daily for 4 weeks in this study showed promising
signals of clinical efficacy in female subjects with IBS-
D, although the a priori endpoints did not achieve sta-
tistical significance. Further evaluation of ONO-2952 is
warranted to assess its potential as a treatment for
IBS-D.
SUPPORTING INFORMATION
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Proportion of subjects (95% CI) reporting
adequate relief from symptoms over time (per-protocol set).
Figure S2. Least-squares mean (s.d.) change from baseline
in weekly scores for number of days free from (a) pain or
(b) urgency (per-protocol set).
Table S1. Sensitivity analysis of overall daily responder
rate in abdominal pain intensity and the composite of pain
intensity and stool consistency, when differing thresholds
for abdominal pain were considered (on-treatment period,
per-protocol set).
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Table S2. Least squares mean (s.d.) and change from
baseline in IBS-QoL, IBS-SSS, HAM-A, HAM-D and PSS
scores (on-treatment period, Per-Protocol Set for IBS-QoL
and Full-Analysis Set for IBS-SSS, HAM-A, HAM-D, PSS).
Table S3. Number of subjects who recorded use of rescue
medication (aspirin, paracetamol or loperamide) for abdom-
inal pain/discomfort, urgency or diarrhoea in the e-diary –
safety analysis set.
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